Literature DB >> 11689887

Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes.

X Chen1, G Scala, I Quinto, W Liu, T W Chun, J S Justement, O J Cohen, T C vanCott, M Iwanicki, M G Lewis, J Greenhouse, T Barry, D Venzon, A S Fauci.   

Abstract

The antigenic polymorphism of HIV-1 is a major obstacle in developing an effective vaccine. Accordingly, we screened random peptide libraries (RPLs) displayed on phage with antibodies from HIV-infected individuals and identified an array of HIV-specific epitopes that behave as antigenic mimics of conformational epitopes of gp120 and gp41 proteins. We report that the selected epitopes are shared by a collection of HIV-1 isolates of clades A-F. The phage-borne epitopes are immunogenic in rhesus macaques, where they elicit envelope-specific antibody responses. Upon intravenous challenge with 60 MID50 of pathogenic SHIV-89.6PD, all monkeys became infected; however, in contrast to the naive and mock-immunized monkeys, four of five mimotope-immunized monkeys experienced lower levels of peak viremia, followed by viral set points of undetectable or transient levels of viremia and a mild decline of CD4+ T cells, and were protected from progression to AIDS-like illness. These results provide a new approach to the design of broadly protective HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689887     DOI: 10.1038/nm1101-1225

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  25 in total

1.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.

Authors:  Keith Mansfield; Sabine M Lang; Marie-Claire Gauduin; Hannah B Sanford; Jeffrey D Lifson; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

3.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

4.  Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

Authors:  Nancy A Wilson; Jason Reed; Gnankang S Napoe; Shari Piaskowski; Andy Szymanski; Jessica Furlott; Edna J Gonzalez; Levi J Yant; Nicholas J Maness; Gemma E May; Taeko Soma; Matthew R Reynolds; Eva Rakasz; Richard Rudersdorf; Adrian B McDermott; David H O'Connor; Thomas C Friedrich; David B Allison; Amit Patki; Louis J Picker; Dennis R Burton; Jing Lin; Lingyi Huang; Deepa Patel; Gwendolyn Heindecker; Jiang Fan; Michael Citron; Melanie Horton; Fubao Wang; Xiaoping Liang; John W Shiver; Danilo R Casimiro; David I Watkins
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Cancer-associated CD43 glycoforms as target of immunotherapy.

Authors:  Franca Maria Tuccillo; Camillo Palmieri; Giuseppe Fiume; Annamaria de Laurentiis; Marco Schiavone; Cristina Falcone; Enrico Iaccino; Ricciarda Galandrini; Cristina Capuano; Angela Santoni; Francesco Paolo D'Armiento; Claudio Arra; Antonio Barbieri; Fabrizio Dal Piaz; David Venzon; Patrizia Bonelli; Franco Maria Buonaguro; Iris Scala; Massimo Mallardo; Ileana Quinto; Giuseppe Scala
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

6.  Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicity.

Authors:  Joan G Schellinger; Lieza M Danan-Leon; Jessica A Hoch; Aemro Kassa; Indresh Srivastava; David Davis; Jacquelyn Gervay-Hague
Journal:  J Am Chem Soc       Date:  2011-02-22       Impact factor: 15.419

7.  Ultrasensitive rapid detection of human serum antibody biomarkers by biomarker-capturing viral nanofibers.

Authors:  Yicun Wang; Zhigang Ju; Binrui Cao; Xiang Gao; Ye Zhu; Penghe Qiu; Hong Xu; Pengtao Pan; Huizheng Bao; Li Wang; Chuanbin Mao
Journal:  ACS Nano       Date:  2015-04-09       Impact factor: 15.881

8.  Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.

Authors:  Michael S Seaman; Sampa Santra; Michael H Newberg; Valerie Philippon; Kelledy Manson; Ling Xu; Rebecca S Gelman; Dennis Panicali; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

10.  Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.

Authors:  Miles P Davenport; Ruy M Ribeiro; Dennis L Chao; Alan S Perelson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.